STAT+: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds

Gilead's oral drug emvistegrast achieved a 23% placebo-adjusted clinical remission rate in a Phase 2 trial in moderate to severe ulcerative colitis, a statistically significant difference. The results with a 200 mg daily dose over 12 weeks exceeded Wall Street analyst expectations. Swati Tole, Gilead's senior vice president of clinical development for inflammatory diseases, said emvistegrast has the potential to become a best-in-class oral therapy for this indication.